Skip to main content
Equibles
JAGX logo

JAGX · Jaguar Health, Inc. · Metrics

Track JAGX — free

Use JAGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JAGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.62 -0.01 (-0.38%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements. While management believes this infusion improves our liquidity, it does not fully alleviate the conditions that raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements.”
View the 10-Q filed Aug 19, 2026
Market Cap
$1.81M
Shares
689,107
Volume · Oct 20 265.7K Avg daily vol (3 sessions) 557.43K

JAGX metrics

47 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.63
Market cap
$1.81M

Price action

20 metrics
Price change (1W)
—
Price change (30D)
-25.4%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
689,107

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 31,408.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 1,534.7%
P / book
0.4
reciprocal yield 271.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2,013.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-19

Profitability

9 metrics
Gross margin
82.3%
Operating margin
-93.1%
Trailing 12 months
Net margin
-131.2%
Gross profit (TTM)
$22.89M
Operating profit (TTM)
−$25.89M
Net income (TTM)
−$36.50M
Trailing 12 months
Diluted EPS (TTM)
$826.05
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-15,522,481.86

Growth

11 metrics
Revenue growth YoY
-58.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$27.82M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,690.7%
Year over year · more shares
Revenue CAGR (3Y)
-1.3%
Revenue CAGR (5Y)
+4.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-741.7%
Return on assets
-106.7%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$23.99M
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
-25.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.79M
Total assets
$34.19M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.68M
Capital expenditures (TTM)
—
R&D (TTM)
$25.23M
SG&A (TTM)
—
Stock compensation (TTM)
$577,000
R&D / revenue
90.7%
Stock compensation / revenue
2.1%

Ownership (13F)

9 metrics
13F filers
8
13F filer change QoQ
-3
Institutional ownership
0.1%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+27.2%
Holder tenure
2.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
24.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1585608 CUSIP 47010C854 13F (30d) 1 filings 1 filers Visit website Investor relations